Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcala de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Medicina (Kaunas). 2022 May 28;58(6):722. doi: 10.3390/medicina58060722.
Breast cancer (BC) is the first diagnosed type of cancer and the second leading cause of cancer-related mortality in women. In addition, despite the improvement in treatment and survival in these patients, the global prevalence and incidence of this cancer are rising, and its mortality may be different according to the histological subtype. Invasive lobular carcinoma (ILC) is less common but entails a poorer prognosis than infiltrative ductal carcinoma (IDC), exhibiting a different clinical and histopathological profile. Deepening study on the molecular profile of both types of cancer may be of great aid to understand the carcinogenesis and progression of BC. In this sense, the aim of the present study was to explore the histological expression of Insulin receptor substrate 4 (IRS-4), cyclooxygenase 2 (COX-2), Cyclin D1 and retinoblastoma protein 1 (Rb1) in patients with ILC and IDC. Thus, breast tissue samples from 45 patients with ILC and from 45 subjects with IDC were analyzed in our study. Interestingly, we observed that IRS-4, COX-2, Rb1 and Cyclin D1 were overexpressed in patients with ILC in comparison to IDC. These results may indicate a differential molecular profile between both types of tumors, which may explain the clinical differences among ILC and IDC. Further studies are warranted in order to shed light onto the molecular and translational implications of these components, also aiding to develop a possible targeted therapy to improve the clinical management of these patients.
乳腺癌(BC)是女性中诊断出的第一大癌症类型,也是癌症相关死亡的第二大主要原因。此外,尽管这些患者的治疗和生存率有所提高,但全球范围内这种癌症的患病率和发病率正在上升,其死亡率可能因组织学亚型而异。浸润性小叶癌(ILC)虽然较少见,但比浸润性导管癌(IDC)预后更差,表现出不同的临床和组织病理学特征。深入研究这两种癌症的分子特征可能有助于了解乳腺癌的发生和发展。有鉴于此,本研究旨在探讨胰岛素受体底物 4(IRS-4)、环氧化酶 2(COX-2)、细胞周期蛋白 D1 和视网膜母细胞瘤蛋白 1(Rb1)在 ILC 和 IDC 患者中的组织学表达。因此,我们对 45 例 ILC 患者和 45 例 IDC 患者的乳腺组织样本进行了分析。有趣的是,我们观察到 IRS-4、COX-2、Rb1 和 Cyclin D1 在 ILC 患者中表达过度,与 IDC 相比。这些结果可能表明这两种肿瘤之间存在不同的分子特征,这可以解释 ILC 和 IDC 之间的临床差异。需要进一步研究以阐明这些成分的分子和转化意义,也有助于开发可能的靶向治疗方法,以改善这些患者的临床管理。